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Uncoupling of invasive bacterial mucosal
immunogenicity from pathogenicity
Simona P. Pfister 1,2,10, Olivier P. Schären 1,2,10, Luca Beldi 1, Andrea Printz1, Matheus D. Notter1,2,
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Mercedes Gomez de Agüero 3, Christian M. Schürch 4,5,6, Fernanda M. Coelho 1, Roy Curtiss III7,
Emma Slack 8, Maria L. Balmer 9 & Siegfried Hapfelmeier 1✉
There is the notion that infection with a virulent intestinal pathogen induces generally
stronger mucosal adaptive immunity than the exposure to an avirulent strain. Whether the
associated mucosal inflammation is important or redundant for effective induction of
immunity is, however, still unclear. Here we use a model of auxotrophic Salmonella infection
in germ-free mice to show that live bacterial virulence factor-driven immunogenicity can be
uncoupled from inflammatory pathogenicity. Although live auxotrophic Salmonella no longer
causes inflammation, its mucosal virulence factors remain the main drivers of protective
mucosal immunity; virulence factor-deficient, like killed, bacteria show reduced efficacy.
Assessing the involvement of innate pathogen sensing mechanisms, we show MYD88/TRIF,
Caspase-1/Caspase-11 inflammasome, and NOD1/NOD2 nodosome signaling to be indivi-
dually redundant. In colonized animals we show that microbiota metabolite cross-feeding
may recover intestinal luminal colonization but not pathogenicity. Consequent immunoglo-
bulin A immunity and microbial niche competition synergistically protect against Salmonella
wild-type infection.
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Mounting a functional anti-microbial adaptive immuneresponse depends on concomitant induction of aninnate immunogenic response through pattern recog-
nition receptor (PRR) activation1. PRRs sense conserved micro-
bial molecular structures, such as bacterial lipopolysaccharide
(LPS), peptidoglycan, and flagellin, that are conserved across
pathogenic and non-pathogenic microorganisms2. Pathogen-
specific virulence factors such as type 3 secretion system (T3SS)
components3 and intracellular toxin action have also been shown
to be specifically sensed by PRRs4,5. The integration of diverse
PRR signals is believed to regulate immune responses according
to the nature of the microbial threat6,7. Natural and artificial PRR
signaling agonists are consequently exploited pharmaceutically as
pro-immunogenic additives or adjuvant components of vaccines8.
Besides the immunogenic response, PRR activation by pathogens
may also drive inflammation and innate anti-microbial defense.
This arm of the innate immune system is important for the
control of primary pathogen infection, but is also responsible for
the adverse effects of inflammation and defense that damage host
tissue and symbiotic microbiota, which may be exploited by some
mucosal pathogens9.
The intestinal mucosal membranes are colonized continuously
with a diverse symbiotic microbiota and are guarded by a com-
plex mucosal immune system. The mucosa is well adapted to
stable symbiosis with non-pathogenic microbes. Multiple physical
and chemical barriers as well as active immune tolerance avoid
the unnecessary activation of immune defense mechanisms by
harmless symbiotic microbes or food antigens10. Only virulent
mucosal pathogens normally induce inflammatory responses.
Avirulent, fully attenuated pathogens are inefficient at driving
inflammation, but also tend to induce less effective adaptive
immunity than virulent pathogens11,12. It is consequently difficult
to induce protective mucosal immunity safely with adequately
attenuated live vaccines—this compromises vaccination efforts in
developing countries for which safe, effective, and easy-to-
administer oral vaccines are urgently needed13,14.
While there is a clear difference between the immune
responses induced by virulent and non-virulent variants of a
pathogenic bacterium, it is unclear which aspects of bacterial
virulence may be differentially sensed by the immune system to
induce efficacious adaptive immunity. Virulence factors enable
pathogens to colonize privileged body sites, overgrow host
defenses, and consequently damage host tissue architecture and
function. Inactivated (killed) pathogenic microbes are avirulent,
because they are sterile and most virulence mechanisms (apart
from, for example, stable exotoxins) are dependent on bacterial
viability. Our question was whether a pathogen that combines
sterility and viability, which expresses molecularly functional
virulence factors in vivo but is unable to replicate, still retains its
mucosal immunogenicity.
To address this question, we apply a quantitative Salmonella
enterica serovar Typhimurium (STm) infection model in germ-
free mice in which live bacterial replication in vivo is blocked. We
use auxotrophic mutants of STm (STmAux) that are genetically
engineered to be fully replication incompetent in germ-free ani-
mals and host tissues. As we previously established in non-
pathogenic enterobacteria15,16, STmAux colonization in germ-free
mice is limited by the quantity of the bacterial inoculum and fully
transient, allowing the germ-free host to return to germ-free
status.
Using germ-free mice, this experimental approach allows us to
rigorously test the following issues. First, whether the mucosal
immunogenic response can distinguish between virulence factor
proficient and deficient intestinal bacteria also in the absence of
an acute inflammatory response and pathology. Secondly, whe-
ther the remaining immunogenic response would depend on
similar PRR signaling pathways as the innate immune defense.
These fundamental studies are carried out in a germ-free setting,
to avoid the possible confounding effect of auxotrophic meta-
bolite crossfeeding by bacteria of the gut microbiota in vivo.
Extending our results into colonized mice, we move on to show
that indeed crossfeeding by the microbiota can recover efficient
intestinal colonization, but not pathogenicity of STmAux. Strictly
confined by the mucosal barrier it then combines virulence
factor-dependent immunogenicity and avirulence with the added
benefit of pathogen niche competition.
Results
Proliferation-incompetent STmAux induces functional immu-
nity. Mucosal tissue invasion and virulence of STm are mediated
by two type 3 secretions systems (T3SS) encoded on Salmonella
pathogenicity islands, SPI1 and SPI2 (refs. 3,17–19). Activity of the
SPI1-encoded T3SS induces early mucosal inflammation20,21. As
the invading and tissue-overgrowing virulent bacteria responsible
are subject to pronounced population bottle necks3,22, we hypo-
thesized that a strain of live STm encoding functional virulence
factors would retain its invasiveness with associated adaptive
immunogenicity, despite being unable to replicate and overall
avirulent.
To test this hypothesis we generated an auxotrophic STm
strain (STmAux) that strictly requires supplementation with the
essential peptidoglycan constituents D-alanine (D-Ala) and meso-
diaminopimelic acid (m-Dap) to grow and survive cell division
(Supplementary Fig. 1A, B). Like the homologous model in
commensal Escherichia coli developed previously15,16, STmAux
colonized the gastrointestinal tract of germ-free mice only
transiently, allowing rapid and full recovery to germ-free status,
as neither host metabolism nor diet could substitute the
auxotrophic requirement for these metabolites (Fig. 1a, b).
Salmonella T3SS competence or deficiency had no effect on
STmAux colonization kinetics. Bacterial quantitation in small
intestinal (Supplementary Fig. 2A) and cecal (Supplementary
Fig. 2B) contents at early time points revealed small intestinal
transit of STmAux in quantities similar to wild-type STm until
2.5 h following inoculation. At 4.5 h, STmAux had transited from
the small intestine into cecum without evidence for replication
(Supplementary Fig. 2A, B; compare STmAux numbers between
small intestine at 2.5 h and cecum at 4.5 h), whereas wild-type
STm populations had begun to expand in the cecum. By 34 h after
inoculation wild-type STm stably colonized all intestinal
segments, whereas STmAux densities had sharply declined. No
spontaneous D-Ala/m-Dap-independent revertants have been
isolated ex vivo during these experiments.
D-Ala/m-Dap auxotrophic bacteria depleted of D-Ala or m-
Dap, analogous to wild-type bacteria exposed to beta-lactam
antibiotics, remain active until self-destruction by programmed
autolytic cell death occurring at the onset of cell division16,23.
Accordingly, D-Ala- and m-Dap-depleted STmAux displayed
normal cell invasiveness, as demonstrated by immunofluores-
cence microscopy and gentamicin protection assay (Fig. 1g, h). In
germ-free mice, following enteral administration of 1010 colony-
forming units (CFU) of STmAux by gavage, the invasive
auxotroph was found to be completely avirulent. In contrast to
wild-type STm, STmAux was rarely recoverable from mesenteric
lymph nodes (mLN), liver, or spleen (Fig. 1f). It no longer
induced detectable levels of typhocolitis (inflammation of the
cecum, the main enteric histopathology in the non-typhoidal
invasive salmonellosis mouse model24) as determined either by
quantification of cecal luminal inflammation marker lipocalin-2
(Fig. 1c) or by histopathologic scoring (Fig. 1d, e). Quantification
of early mRNA markers of chemokine and other innate activation
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signals in total cecum tissue supported the conclusion that
STmAux is avirulent (Supplementary Fig. 2C).
Transitory intestinal mucosal conditioning by live STmAux
bacteria (Fig. 2a) induced an adaptive immune response highly
protective against the re-challenge of the germ-free animals with
non-auxotrophic wild-type STm. While immunity had no effect
on the large intestinal luminal load of the challenge strain
(Fig. 2b), it protected against its intestinal pathogenesis (Fig. 2c,
d) and limited penetration to the mLNs, liver, and spleen
(Fig. 2e). Protective immunity was associated with high STm-
specific titers of intestinal secretory IgA measured by live bacterial
flow cytometry25 (Fig. 2f, g), and was abolished in B cell- and
antibody-deficient JH−/− mice (Fig. 2h–j). B and T cell-deficient
RAG-deficient mice phenocopied JH-deficient mice (Supplemen-
tary Fig. 3A–D). Hence, B cell immunity is functionally required
for STmAux-induced intestinal protective immunity. The live
STmAux dose–response relationship was examined by comparing
the mucosal conditioning with doses of 1010, 108, and 106 live
STmAux, which revealed that induction of functional immunity
required doses greater than 108 live STmAux (see extended dataset
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in Supplementary Fig. 4A–G). Thus, STmAux allowed us to probe
mucosal immunity in a strictly dose-dependent manner. This
data showed the threshold effects of STmAux conditioning in
germ-free mice, which would not be achievable with conventional
non-auxotrophic bacteria that would exponentially expand
rapidly to reach high intestinal densities independently of
inoculum size.
Optimal protective efficacy of STmAux is viability dependent.
We next addressed how relevant STmAux viability is for the
induction of functional intestinal immunity. The replication
incompetency of live STmAux in germ-free mice allowed us to
quantitatively compare the functional effects of mucosal exposure
to live versus killed STm: both live and killed STmAux cells are
sterile entities in germ-free mice. Parallel groups of germ-free
mice were intestinally conditioned by gavage with STmAux
inocula administered either live or following inactivation by
peracetic acid (PAA) treatment. PAA killing is highly effective
and has been shown to preserve mucosally protective STm sur-
face B cell epitopes26,27. Naïve germ-free animals served as
negative controls. Four weeks after the first treatment, the germ-
free animals of all three groups were challenged orally with
virulent wild-type STm and studied at days 1 and 4 after the
challenge, respectively (Fig. 3a). Compared to live STmAux-con-
ditioned mice, PAA-killed STmAux-induced STm-specific IgA
titers were reduced at day 1 of challenge (Fig. 3b, Supplementary
Fig. 5). Yet, by day 4 this difference was no longer apparent.
However, while pretreatment with either PAA killed or live
STmAux were similarly protective against early wild-type STm-
induced mucosal inflammation at day 1 after challenge, only live
STmAux preconditioning provided effective protection from
intestinal pathology and organ infection until day 4 (Fig. 3c–g).
Notably, live STmAux-induced immunity not merely delayed the
onset of disease, but protected the germ-free mice from lethal
STm infection. Live STmAux-conditioned germ-free mice that
were followed up for 3 weeks following challenge remained free of
macroscopic evidence of severe infection and were recovering at
the time of sacrifice (Supplementary Fig. 6). None of these effects
were explained by differences in fecal or cecal luminal coloniza-
tion levels of the challenge strain, which were similar across all
experimental groups (Fig. 3h, i, Supplementary Fig. 6B).
Salmonella type 3 secretion signifies robust immunogenicity.
We next asked whether or not the viability-dependency of
functional mucosal immunogenicity of STmAux is virulence factor
related. We hypothesized that host interaction through Salmo-
nella T3SSs (whose function is energy and viability dependent)
signifies the functional immunogenicity of live STmAux. If this
was true, T3SS deficiency would diminish the mucosal efficacy of
live STmAux.
We tested this hypothesis by comparing the protective effect of
the enteral conditioning of germ-free mice with matching doses
of live T3SS-competent and isogenic T3SS-deficient mutant
strains of STmAux (STmAux T3SS−). Two different isogenic
STmAux T3SS− mutants were tested: a complete SPI1 and SPI2
genomic island deletion mutant (ΔSPI1 ΔSPI1) devoid of T3SS
genes entirely28, and a ΔinvC ΔssaV mutant expressing defective
T3SSs29,30. Mice treated with equivalent doses of PAA-killed
STmAux or naïve mice served as controls. Four weeks after the
first treatment, the germ-free animals were enterally challenged
with wild-type STm, and studied at days 1 and 3 after challenge
(Fig. 4a). Analysis of the severity of challenge infection and
mucosal pathology at day 3 revealed that live, T3SS-deficient
STmAux strains induced less robust functional protective
immunity than T3SS-competent STmAux, and their efficacy
against intestinal mucosal pathology (Fig. 4b, c) and bacterial
penetration to mLN (Fig. 4d) was no longer significantly better
than that of PAA-killed STmAux. Genetic deletion of the three
most important SPI1 effector protein genes (sopE, sopE2, and
sipA) required for early SPI1 T3SS-mediated intestinal STm
pathogenesis31 also resulted in reduced efficacy (Supplementary
Fig. 7). This suggests that not merely immune recognition of a
functional T3SS apparatus but rather mucosal pathogenesis-
related type 3 effector protein functions are driving the superior
immunogenicity of the T3SS-competent STmAux strain.
As in the previous experiment (Fig. 3b) killed STmAux- as well
as STmAux T3SS−-preconditioned mice displayed reduced STm-
specific IgA titers at day 1 of challenge (Fig. 4e, Supplementary
Fig. 8). Yet, by day 3 mice of all three treatment groups had
similar intestinal IgA titers. Immunoglobulin repertoire sequen-
cing analysis of small intestine and mLN revealed overlapping
IgA repertoires following mucosal conditioning with live T3SS-
competent STmAux- versus T3SS-incompetent STmAux that
clustered separately from those of naïve germ-free control mice
Fig. 1 Transient colonization of GF mice with STmAux. a Mice were inoculated at day 0 with 1010 CFU of either auxotrophic (Aux; red symbols) or non-
auxotrophic control (black symbols) STm strains that were either type 3 secretion competent (STm/STmAux, filled symbols) or isogenic type 3 secretion-
deficient mutants (STmT3SS−/STmAux T3SS−, open symbols). b Time course of viable bacteria of each strain recoverable from feces (STmAux n= 32,
STmAux T3SS− n= 15, STmT3SS− n= 12, STm n= 11, animals examined over nine independent experiments). c Lipocalin-2 concentration in cecal contents at
9 h after inoculation (STmAux n= 5, STmT3SS− n= 5, STm n= 5 animals). d Cecal histopathology score at 9 h after inoculation. Each symbol represents
one individual (STmAux n= 5, STmT3SS− n= 5, STm n= 5 animals). e Cecal histology at 9 h after inoculation with indicated STm strains. H&E staining.
Scale bar: 100 μm (STmAux n= 5, STmT3SS− n= 5, STm n= 5 animals). f Organ loads of T3SS-proficient STmAux and STm in mLN, liver, and spleen on day
1 (mLN: STmAux n= 18, STm n= 3; liver: STmAux n= 6, STm n= 2; spleen: STmAux n= 9, STm n= 3 animals examined over four independent
experiments) and 3 (mLN: STmAux n= 2, STm n= 3; liver: STmAux n= 2, STm n= 3; spleen: STmAux n= 2, STm n= 3 animals examined over two
independent experiments) post inoculation. g Immunofluorescence of HeLa cells infected for 2 h with wild type (STm), SPI1 T3SS-deficient (STmΔinvC),
auxotrophic SPI1 T3SS-proficient (STmAux), and auxotrophic SPI1 T3SS-deficient (STmAux ΔinvC) STm. Cells were stained with DAPI (DNA/nuclei, blue),
and with anti-STm group B antiserum and labeled secondary antibodies consecutively before, and after membrane permeabilization to differentiate
extracellular (red+ green) and intracellular (green only) STm. Scale bar: 10 µm (six samples were examined over two independent experiments for each
condition). h Quantification of gentamicin-protected intracellular STmAux ΔinvC (black open circles, n= 6 wells examined over two independent
experiments), STmΔinvC (black filled circles, n= 6 wells examined over two independent experiments), STmAux (red open triangles, n= 6 wells examined
over two independent experiments), and STmΔinvC (red filled triangles, n= 6 wells examined over two independent experiments) in HeLa cells 2 h after
infection. Statistics: bars indicate mean (c, f, h) or median (d) values. Horizontal dotted lines indicate the lower limit of detection (b, c, f, h). Panel c was
analyzed with ordinary one-way ANOVA and Tukey’s test for multiple comparison. Panel d was analyzed with a two-sided multicomparison Kruskal–Wallis
test and Dunn’s post hoc test. Panel f was analyzed with unpaired two-tailed t-test for each day. Panel h was analyzed with two-way ANOVA (virulence
and auxotrophy as the two factors) and Sidak multiple comparison correction. Source data are provided as a Source Data file. Detailed statistical metrics
are available in the Supplementary Statistical Analysis file.
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(Supplementary Fig. 9). Repertoire overlap was measured by
calculating the geometric mean of relative overlap frequencies
between CDR3 amino acid sequence usage (see Methods section).
Preprocessed clonotype amino acid sequences and metadata
description are available as supplementary data files (Supple-
mentary Data 1–21).
O-serotype specific IgA has been shown previously to be a
necessary component of any intestinal immune protection
induced by killed or live STm12,26,27. O-antigen is a dominant
polysaccharide antigen and in binding assays tends to mask other
surface epitopes from antibody recognition, which is the basis of
O-serotyping. To specifically study O-serotype-independent
Salmonella surface binding IgA, germ-free mice were precondi-
tioned with STmAux but challenged with the different Salmonella
serotype Enteritidis (SEn) (Supplementary Fig. 10A). The resulting
intestinal IgA had reduced surface reactivity towards O-antigen-
deficient (rough) STm compared to wild-type (smooth) STm, as
expected (Supplementary Fig. 10B, C). However, the non-O-
antigen-specific IgA cross-reacted between rough STm and
rough SEn (Supplementary Fig. 10B, C). It also cross-reacted
with smooth wild-type SEn, suggesting that it contributes to
serotype-independent Salmonella surface reactivity (Supplemen-
tary Fig. 10B, C). Although the O-serotype-independent IgA
component alone is insufficient12,26,27, it may complement
a
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p < 0.0001
p < 0.0001
p = 0.0020
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p < 0.0001
Fig. 2 Intestinal conditioning of GF mice with STmAux induces B cell dependent functional intestinal immunity. a Germ-free mice were enterally
conditioned with six doses of 1010 CFU of STmAux (red triangles, n= 5 animals) or were left untreated (gray-filled circles, n= 5 animals). Four weeks after
the first treatment (day 0) mice were challenged with wild-type STm (105 CFU) and analyzed 2 days later. Each symbol represents one individual.
b Shedding of wild-type STm in feces 1 day after challenge. c Cecal histopathology score at day 2 after challenge. Each symbol represents one individual.
d Lipocalin-2 concentration in cecal contents at day 2 after challenge. e Bacterial burden of wild-type STm in mLNs, spleens, and livers at day 2 after
challenge. f Intestinal secretory IgA was isolated at day 2 after challenge. IgA binding to wild-type Salmonella was quantified at different antibody
concentrations by live bacterial flow cytometry. Connected symbols represent one individual. g STm-specific titer (−logEC50) calculated from the STm-IgA
titration curve plotted in Fig. S4J. h Experimental design: Germ-free Jh−/− (open symbols, n= 5 animals) and wild-type control mice (filled symbols, n= 4
animals) were enterally conditioned three times with 1010 CFU of live STmAux. Thirty-three days after the first treatment (day 0) all mice were challenged
with of wild-type STm (103 CFU). i Bacterial burden of wild-type STm in mLNs, spleens, and livers at day 3 after challenge. j Lipocalin-2 concentration in
cecal contents at day 3 after challenge. Statistics: bars indicate mean (b, d, e, g, i, j) or median (c) values. Horizontal dotted lines indicate the detection
limit. Panel c was analyzed with a two-sided Mann–Whitney U-test. Panels d, e, g, i and j were analyzed with the unpaired two-tailed t-test. Source data are
provided as a Source Data file. Detailed statistical metrics are available in the Supplementary Statistical Analysis file.
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O-antigen-specific IgA in protective mucosal immunity. Support-
ing this idea, we found that, although both killed and T3SS-
deficient STmAux preconditioning at day 3 of challenge resulted in
robust IgA titers towards smooth STm (Fig. 4e, panel Day 3), IgA
binding to rough STm was significantly reduced (Fig. 4f).
These data show that Salmonella T3SS-dependent virulence
functions signify the mucosal immunogenic efficacy of life
STmAux in absence of inflammation. The underlying T3SS-
dependent IgA B cell response is characterized by a less O-
antigen-restricted bacterial surface reactivity.
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PRR signaling redundancy in induction of immunity. Innate
pathogen recognition through PRRs is critical in the defense
against primary STm infection. MYD88 knockout mice lacking
TLR and IL1R family downstream signaling are consequently
severely impaired in innate immunity against mucosal
STm infection17,19. Canonical Caspase-1-dependent and non-
canonical Caspase-11 (Caspase-4 in humans)-dependent inflam-
masome activation have also been implicated in innate immune
control of STm infection32. The NLRC4 inflammasome is acti-
vated by the SPI1 T3SS needle complex proteins and therefore
may mediate innate recognition of T3SS-competent intestinal
STm specifically3. Moreover, the NOD1/NOD2 nodosome has
been reported to respond to bacterial pathogenicity by sensing
the cytoplasmic activities of Salmonella SPI1 T3SS-1 effector
proteins4.
Are these also factors individually important for the induction
of functional adaptive immunity in the absence of an inflamma-
tory response? To address this we tested the hypothesis that
deficiencies for innate recognition pathways critical in innate
immune defense also affect induction of functional adaptive
immunity by live STmAux. Mice deficient in (i) TLR/IL1R family
adaptor proteins MYD88 and TRIF, (ii) Caspase-1 and Caspase-
11, (iii) NLRC4, and (iv) NOD1 and NOD2 were derived germ
free and compared with innate immunocompetent control mice
for their adaptive immune responses towards live STmAux.
Using STmAux avoids bacterial overgrowth of severely innate
immunodeficient hosts that lack control and containment of
intestinal microbes, leading to increased mucosal penetration also
of attenuated, avirulent, and commensal bacteria. In MYD88/
TRIF double-deficient mice this has been shown to result in
abnormally high systemic exposure to gut commensals and
consequent compensatory B cell immunity. Involvement of
redundant innate signaling pathways triggered by massively
increased microbial loads has been postulated to be responsible
but has not been characterized further33. The STmAux model in
germ-free mice, however, uniquely fixes the bacterial load per
animal and consequently avoids bacterial overgrowth to skew
immune activation.
First, germ-free MYD88/TRIF double-deficient and wild-type
control mice were enterally conditioned with live STmAux. Four
weeks after the first treatment all mice were challenged orally with
wild-type STm harboring an intracellularly inducible GFP
reporter plasmid (pM973)17 and studied at day 3 after the
challenge (Fig. 5a). Control groups of both genotypes were
challenged but without STmAux preconditioning. Quantification
of cecal mucosal (Fig. 5b, Supplementary Fig. 11A), mLN, liver,
and spleen (Fig. 5c) burdens of STm[pM973] revealed that the
induction of functional immunity by live STmAux was robust
even in the highly susceptible MYD88/TRIF double-deficient
mice. At day 3 post challenge, bacterial loads in mLN, livers, and
spleens of STmAux-treated MYD88/TRIF-deficient mice were
similar to, and in cecal mucosal tissues even lower than, those in
the STmAux-treated wild-type animals. In accordance with this
relatively greater effect of STmAux treatment in mutant than wild-
type mice, a two-way ANOVA revealed a significant interaction
between the effects of genotype and STmAux treatment (p <
0.0001 for all panels; for detailed statistical metrics see Statistical
Analysis file available as Supplementary Information). Quantita-
tion of cecal luminal lipocalin-2 and histopathology scores both
confirmed the protective effects of STmAux treatment within each
mouse genotype (Supplementary Fig. 11B, C), although these two
readouts themselves are MYD88/TRIF-dependent17,34 and should
therefore be compared between both mouse genotypes with
caution.
We next tested the ability of live STmAux to induce adaptive
immunity in NOD1/NOD2-double-knockout mice (Fig. 6a–c),
NLRC4-deficient mice, and Caspase-1/11 double-deficient mice
(Fig. 6d–f), all of which at day 3 of challenge were found to have
no deficiency in mounting functional mucosal immunity towards
live STmAux conditioning (two-way ANOVA, for detailed
statistical metrics see Statistical Analysis file available in the
Supplementary Information).
These results show that MYD88/TRIF, Caspase-1/Caspase-11
inflammasome, and NOD1/NOD2 nodosome signaling were
individually redundant for the induction of adaptive immunity by
live STmAux in the absence of inflammation. Their role in
complementing adaptive immunity in pathogen clearance at later
stages of secondary infection is likely functionally important,
although not apparent at day 3 of challenge.
Microbiota-dependent colonization and niche competition. So
far, the fully reversible germ-free mouse model uniquely had
allowed the quantitative study of the immunogenicity of dif-
ferent phenotypes of STmAux in a very clean system. However,
in real-life situations STmAux would interact also with the
indigenous gut microbiota, which we hypothesized to provide
crossfeeding of the required cell wall metabolites in vivo. This
may delay STmAux intestinal luminal clearance in colonized
mice. We tested this hypothesis using a well-established gno-
tobiotic mouse model that is stably colonized with 12 repre-
sentative murine intestinal taxa [stable defined moderately
diverse mouse microbiota (sDMDMm)35] all of which are fully
sequenced and openly available as pure cultures from the
“Deutsche Sammlung von Mikroorganismen und Zellkulturen”
(DSMZ)36,37. The sDMDMm model has proven merit for the
study of intestinal STm infection and its interaction with the
commensal microbiota without the need for harsh antibiotic
treatments, and shows relevant phenotypic effects such as lim-
iting the colonization of STm38.
Fig. 3 Optimal mucosal efficacy of STmAux is viability dependent. a Germ-free mice were enterally conditioned with four doses of 1010 CFU STmAux
(filled red triangles, n= 10 animals), PAA-killed STmAux (filled blue diamonds, n= 11 animals), or were left untreated (gray-filled circles, n= 10 animals).
Four weeks after the first treatment (day 0) mice were challenged with wild-type STm (104 CFU). Mice were sacrificed at day 1 and day 4 after challenge
with wild-type STm, respectively. Each symbol represents one individual. b STm-specific titer (logEC50) of intestinal secretory IgA determined by live
bacterial flow cytometry. c, d Lipocalin-2 concentration in feces (c) and cecal content (d) at day 0–4 after challenge. (e) Cecal histopathology score at days
1 and 4 after challenge, respectively. Each symbol represents one individual. Data points depicted with an arrow are shown in panel f. f Cecal histology at
day 1 and day 4 after challenge, respectively. H&E staining of cryosections. Scale bar= 100 μm. g Bacterial burden of wild-type STm in mLNs, spleens, and
livers at days 1 and 4 after challenge, respectively. h Fecal colonization of wild-type STm at days 0–4 after challenge (inset graph: quantification of STmAux
in feces at day 0 confirming germ-free status at day 0). i Cecal luminal colonization of wild-type STm at day 4 after challenge. Statistics: bars indicate mean
(b–d, g–i) or median values (e). Horizontal, dotted lines indicate the detection limit (b–d, g–i). Panel b was analyzed with an unpaired two-tailed t-test
(control group excluded from test). Panels c, d, and g were analyzed with ordinary one-way ANOVA and Dunnett’s post hoc test (comparison to control
group). Panel e was analyzed with a two-sided multicomparisons Kruskal–Wallis test and Dunn’s post hoc test. Source data are provided as a Source Data
file. Detailed statistical metrics are available in the Supplementary Statistical Analysis file.
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Following a single inoculation with 107 STmAux by gavage,
sDMDMm mice showed efficient and stable colonization of
STmAux, reaching luminal densities similar to those of isogenic
non-auxotrophic strains, including partly attenuated SPI2
TTSS-deficient (ΔssaV) and avirulent SPI1/SPI2 double-
deficient (ΔinvC ΔssaV) STm (Fig. 7a). STmAux did not revert
to lose its auxotrophic phenotype during these experiments (no
recovery of STm growth from ex vivo intestinal samples in
non-supplemented control medium). Even STmAux re-isolated
from an sDMDMm mouse after 8 months colonized germ-free
mice fully reversibly. Following gavage of 1010 CFU of either
the 8-month re-isolate or the original lab strain, all mice (n= 5
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Fig. 4 Salmonella type 3 secretion signifies robust live STm mucosal immunogenicity. a Germ-free mice were enterally conditioned with three
successive doses of 1010 CFU of live STmAux (red upright triangles, n= 6 animals examined over two independent experiments), live T3SS-double-deficient
STmAux (STmAux ΔinvC ΔssaV, orange squares, n= 6 animals examined over two independent experiments), a live STmAux T3SS-double-deficient SPI1/SPI2
double-deletion mutant (STmAux ΔSPI1 ΔSPI2; purple inverted triangles, n= 6 animals examined over two independent experiments), PAA-killed STmAux
(blue diamonds, n= 6 animals examined over two independent experiments), or PBS vehicle only (ctrl; gray circles, n= 6 animals examined over two
independent experiments). Four weeks after the first treatment (day 0) all mice were challenged with wild-type STm (103 CFU). Mice were analyzed on
day 3 after challenge. Each symbol represents one individual. b Lipocalin-2 concentration in cecal contents at day 3 after challenge. c Cecal histopathology
score at day 3 after challenge. Each symbol represents one individual. d Bacterial burden of wild-type STm recoverable from mLNs at day 3 after challenge.
e STm-specific titer of intestinal secretory IgA at days 1 and 3 after challenge determined by live bacterial flow cytometry. f Rough STm-specific titer of
intestinal secretory IgA at day 3 after challenge determined by live bacterial flow cytometry. Statistics: bars indicate mean (b, d, e) or median values (c).
Horizontal, dotted lines indicate the detection limit (b, d, e). Panels b, d, and e were analyzed with ordinary one-way ANOVA and Dunnett’s post hoc test
(comparison to STmAux group). Panel c was analyzed with a two-sided multicomparisons Kruskal–Wallis test and Dunn’s post hoc test. The data were
pooled from three independent experiments. Source data are provided as a Source Data file. Detailed statistical metrics are available in the Supplementary
Statistical Analysis file.
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per group) had recovered to germ-free status at day 2 post
inoculation.
Despite efficient luminal colonization and evidence for
epithelial invasion of STmAux (Fig. 7e), neither deep mucosal
penetration to mLN and systemic organs nor mucosal pathology
were evident in either wild type (Fig. 7b–d) or MYD88/TRIF-
deficient (Fig. 7f) sDMDMm mice. Thus, while crossfeeding by
sDMDMm organisms can rescue gut luminal colonization, it was
insufficient to recover pathogenicity of STmAux, which is
consistent with the local intestinal luminal confinement of the
crossfeeding microbiota and the activity of D-amino acid
degrading enzymes in host tissues and intestinal mucus39.
Nevertheless, induction of STm-specific IgA was seen after
4 weeks of colonization, which, in contrast to colonization
efficiency, was dependent on SPI1 T3SS competence (Fig. 7g,
Supplementary Fig. 12). As an added host benefit, stably
colonizing STmAux further provided robust niche competition
to a subsequent oral challenge by wild-type STm (Fig. 7h blue
symbols, and Supplementary Fig. 13B). Notably, pre-colonization
with SPI1 T3SS-incompetent STmAux ΔinvC provided only partial
niche competition (Fig. 7h, black symbols, Supplementary
Fig. 13B). SPI1/SPI2 double-deficient STmAux T3SS− showed the
exact same phenotype (Fig. 7h, green symbols, Supplementary
Fig. 13B), supporting the conclusion that SPI1 T3SS-dependent
virulence factors are mainly responsible. In RAG knockout mice
also T3SS-competent STmAux showed inefficient intestinal niche
competition (Supplementary Fig. 14A–D). These findings are
consistent with the interpretation that STmAux-induced host
a
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Fig. 5 Mucosal induction of adaptive immunity by live STmAux is robust in MYD88/TRIF double-deficient mice. a Germ-free MYD88−/−TRIFlps/lps
mice (open symbols) and wild-type control mice (filled symbols) were enterally conditioned with three doses of 1010 CFU of live STmAux (red triangles,
n= 7 MYD88/TRIF KO animals and n= 9 wild-type animals examined over two independent experiments) or left untreated as controls (gray circles, n= 6
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mice were challenged with wild-type STm (103 CFU) harboring ssag::eGFP reporter plasmid pM973. The mice were studied at day 3 after challenge. Each
symbol represents one individual. b Quantification of intracellular wild-type STm expressing eGFP in the cecal mucosa. c Bacterial burden of wild-type STm
recoverable from mLN, spleen, and liver at day 3 after challenge. Statistics: bars indicate mean (b, c). Horizontal, dotted lines indicate the lower detection
limit (b, c). Panels b and c were analyzed with two-way ANOVA (host genotype and treatment as factors) and Sidak multiple comparison correction. The
data were pooled from two independent experiments. Source data are provided as a Source Data file. Detailed statistical metrics are available in the
Supplementary Statistical Analysis file.
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immunity synergizes with niche competition by STmAux in
protection against wild-type STm challenge. Measurements of
cecal luminal lipocalin-2 and challenge bacterial burden in mLN,
liver, and spleen at day 4 of wild-type STm challenge support this
conclusion (Fig. 7i, j, Supplementary Fig. 14D). In a second
context, streptomycin pre-treated conventional mice, a widely
used mouse model for nontyphoid invasive salmonellosis9,24,40,
were also permissive for extended gut luminal colonization of
STmAux (Supplementary Fig. 13C).
These data show that in the colonized mouse model, microbiota-
syntrophic STmAux more closely mimics the natural pathogen in
terms of intestinal luminal colonization and virulence factor-driven
b
C
F
U
/o
ra
gn
C
F
U
/o
ra
gn
p < 0.0001
p < 0.0001
ed
Translocation of wild type STm to organs
Translocation of wild type STmto organs
Liver day 3
p < 0.0001 p < 0.0001
Spleen day 3
101
102
103
104
105
101
102
103
104
105
101
102
103
104
105
101
102
103
104
105
p < 0.0001 p = 0.0005
mLNs day 3
NOD1/2–/– wt
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
ct
rl
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
NOD1/2–/–
NLRC4–/–
CASP1/11–/–
CASP1/11+/–
wt
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
NOD1/2–/– wt
a
Ctrl
Germ-free
–27
Days
1–20 –13 0 32
–27
Days
1–20 –13 0 32
1010
Ctrl
1010
STmAux
STmAux
STmAux
Ctrl
1010
Ctrl
1010
Ctrl
1010
wt
NOD1/2–/–
Wild type STm
challenge
Transitory
conditioning 
Germ-free
Wild type STm
challenge
Transitory
conditioning Liver, day 3 Spleen, day 3 
p = 0.0007
p = 0.0002
p = 0.0005
p < 0.0001
p < 0.0001
p < 0.0001p < 0.0001
p = 0.0004
p = 0.0001
101
102
103
104
105
106
101
102
103
104
105
106
101
102
103
104
105
106
101
102
103
104
105
106
mLN, day 3
NLRC4–/– CASP
1/11–/–
CASP
1/11+/-
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
C
tr
l
S
T
m
A
ux
NLRC4–/– CASP
1/11–/–
CASP
1/11+/-
NLRC4–/– CASP
1/11–/–
CASP
1/11+/-
NLRC4–/– CASP
1/11–/–
CASP
1/11+/-
p < 0.0001
p < 0.0001
p < 0.0001
f Lipocalin-2 in cecumcontent
Day 3
c
p < 0.0001 p < 0.0001
Lipocalin-2 in cecum content
Day 3
ng
/g
ng
/g
NOD1/2–/– wt
STmAux
STmAux
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15891-9
10 NATURE COMMUNICATIONS |         (2020) 11:1978 | https://doi.org/10.1038/s41467-020-15891-9 | www.nature.com/naturecommunications
induction of IgA immunity12. Thus, independently of germ-free
conditions, also stable intestinal STmAux colonization allows
uncoupling of intestinal immunogenicity from pathogenicity, with
the added benefit of luminal pathogen niche competition.
Discussion
Fully attenuated or inactivated pathogens have long been noted to
be poorly protective mucosal immunogens compared to more
virulent strains11–13,41. This has been attributed mainly to the
capacity of virulent pathogens to induce more vigorous innate
immune responses6 and to penetrate into and overgrow inductive
sites of the mucosal immune system11. Here we show specifically
that invasive Salmonella cells expressing live type 3 secretion
systems are recognized by the immunogenic response, indepen-
dently of their propensity to deeply penetrate and replicate as live
organisms inside host tissues or the induction of a marked
mucosal inflammatory response. These data suggest that the
mucosal immune system reacts not only to a damaging infection
but can also recognize stereotypic activities of pathogens more
directly, and thus potentially more sensitively and rapidly. Con-
sequently, a small number of highly transient mucosal exposures
with virulence factor-competent STmAux robustly induce highly
effective immunity in germ-free mice, in the absence of an
inflammatory response. The underlying B cell response induced
by live, virulence factor-competent STmAux is characterized by
the production of intestinal IgA with increased O-serotype-
independent Salmonella surface reactivity. Additional future work
will be required to address which effector T cell activities may
additionally contribute to STmAux-induced immunity42.
It has been described previously that bacterial viability itself is
an important determinant of bacterial immunogenicity, inde-
pendent of pathogenicity and replication competence43. Live
apathogenic bacteria are more immunogenic live than killed
when administered parenterally43. This difference was revealed to
be mediated by innate immune recognition of bacterial messenger
RNA (mRNA), highly unstable, hence normally viability-asso-
ciated, molecules. The underlying sensing pathway for bacterial
mRNA was shown to be dependent on TLR8 and TRIF in
humans, and on TRIF, Caspase-1 and Caspase-11 in mice43–45.
Here we observed only a minor difference in intestinal mucosal
immunogenicity between avirulent live and killed STmAux (see
Fig. 4), which may be mediated by the same mechanism. Viru-
lence factor-competent invasive STmAux, however, was much
more efficacious. Its epithelial invasiveness may increase sub-
epithelial live antigen delivery and consequently prime immunity
more efficiently by delivering live bacteria into the tissues.
However, its immunogenicity was robust even in MYD88/TRIF
and Caspase-1/-11 deficient mice, and thus may not be fully
explained by the same live bacterial sensing pathway. Our data
confirm and extend previous findings of functional redundancy
between innate and adaptive immune responses in the control of
intestinal commensal bacteria33 and the efficacy of established
model vaccines with adjuvant46 in MYD88/TRIF double-deficient
mice. Here we show that this extends also to intestinal pathogenic
bacteria. The remarkable robustness of this system may represent
an evolutionary adaptation to pathogens that evade or alter the
innate immune defense.
Long-established live STm vaccine strains like SPI2 T3SS-
deficient47 and aromatic amino acid auxotrophic aro mutants48
of STm also are effective mucosal immunogens, but are not fully
growth deficient in host tissues and consequently considered
dangerous for HIV positive and other immunocompromised
individuals (reviewed in ref. 14). This has so far ruled out approval
for human application. On the other hand, peptidoglycan meta-
bolite auxotrophic STm strains similar to the one we presented in
this paper have been developed previously49 but in this form have
been considered insufficiently immunogenic because of their poor
mucosal penetration. This conclusion is however predicated on
the preclinical study mainly in conventional rodent models that
are (like humans) intestinally colonization resistant against Sal-
monella9. In this context, when STmAux proliferation in the
intestinal lumen is inhibited by the competing microbiota, its
colonization dynamics would be expected to be more similar to
the germ-free mouse model, and it may consequently require very
high oral doses (as we saw in germ-free mice) to be efficacious.
Instead, the field has moved into the direction of developing more
sophisticated strains that display regulated delayed in vivo
attenuation/lethality phenotypes, allowing for transient survival,
replication, and tissue invasion in vivo11. These highly innovative
approaches are inherently more difficult to combine with safety
parameters matching those of the constitutively D-Ala/Dap aux-
otrophic strain. The presented experiments in non-colonization-
resistant mouse models highlight yet another possible strategy.
The remarkably efficient gut luminal microbiota-syntrophy per-
mitted extended mucosal stimulation with live virulence factor-
competent STmAux, without compromising the strain’s deficiency
in causing pathology and systemic infection. This phenotype
could potentially be exploited further by metabolic engineering of
STmAux strains to gain intestinal colonization efficiency, or by
temporal reduction of colonization resistance in the host at the
time of treatment (preferably other than by antibiotic treatment).
However, given that our conclusions so far are based on mouse
models that have laboratory levels of microbiota complexity,
additional work in more relevant preclinical models will be
necessary to assess potential translatability of these findings for
veterinary or human medical applications.
Fig. 6 NOD1/2, NLRC4 and Caspase-1/11 are individually redundant for mucosal induction of adaptive immunity by live STmAux. a Germ-free NOD1/2-
double-deficient mice (open symbols) and wild-type control mice (filled symbols) were either enterally conditioned with three doses of 1010 CFU of
STmAux (red triangles, n= 11 NOD1/2 KO animals and n= 5 wild-type animals examined over two independent experiments) or left untreated (gray circles,
n= 11 NOD1/2 KO animals and n= 6 wild-type animals examined over two independent experiments). Twenty-seven days after the first treatment (day 0)
all mice were challenged with wild-type STm (103 CFU) and sacrificed at day 3 after challenge. b Bacterial burden of wild-type STm recoverable from mLN,
spleen, and liver at day 3 after challenge. c Lipocalin-2 concentration in cecal contents at day 3 after challenge. d Germ-free NLRC4−/− mice (open
diamonds), Caspase-1/11−/− mice (CASP1/11−/−, open triangles), and control mice (CASP1/11+/− NLRC4+/+ littermate control mice; filled triangles)
were either enterally conditioned with three doses of 1010 CFU of STmAux (red symbols, n= 7 NLRC4−/− animals, n= 7 Caspase-1/11−/−, and n= 7
Caspase-1/11+/− animals examined over two independent experiments) or left untreated (gray symbols, n= 5 NLRC4−/− animals, n= 8 Caspase-1/11−/−,
and n= 7 Caspase-1/11+/− animals examined over two independent experiments). Twenty-seven days after the first treatment (day 0) mice were
challenged with wild-type STm (103 CFU) and sacrificed at day 3 after challenge. e Bacterial burden of wild-type STm recoverable from mLN, spleen, and
liver at day 3 after challenge. f Lipocalin-2 concentration in cecal contents at day 3 after challenge. Each symbol represents one individual. Statistics: bars
indicate mean (b, c, e, f). Horizontal, dotted lines indicate the lower detection limit. Panels b, c, e, f were analyzed with a two-way ANOVA (host genotype
and treatment as factors) and Sidak multiple comparison correction. The data were pooled from two independent experiments. Source data are provided as
a Source Data file. Detailed statistical metrics are available in the Supplementary Statistical Analysis file.
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Methods
Bacterial strains, plasmids, and culture media. The bacterial strains and plas-
mids used in this study are listed in Table 1. Auxotrophic strain HA135 (STmAux,
UK-1 background) [ΔmetC::TetRA Δalr ΔdadX Δasd] was generated from strain
χ9052 [Δalr3 ΔdadB4 ΔasdA33] by replacing the coding region of metC with a
TetRA resistance cassette by Lambda Red recombineering using recombineering
plasmid pSIM5 (ref. 50) as described in ref. 51. Isogenic mutant alleles ΔinvC::aphT,
ΔinvC::aphT ΔssaV::cat, and Δ(avrA-invH::cat) Δ(ssaG-ssaU::aphT) were
transferred into the STm and STmAux backgrounds by phage P22-mediated
transduction using the donor strains M736, M73831 and χ9650 (ref. 28), respec-
tively, as described52. Auxotrophic strain HA623 (SL1344 background) [ΔmetC
ΔalrN ΔalrP Δasd] was generated from strain SL1344 (SB300) by in-frame deletion
of each gene. This was achieved be generation of four single deletion mutants in
SL1344 using the plasmid pSIM6 encoded Lambda Red recombinase system50 for
allelic exchange of the coding sequence (leaving the stop codon) with a Tet
selectable tetA-sacB cassette, followed by four sequential rounds of P22
a h i
jb c
d
e f g
p = 0.0002
p < 0.0001 p = 0.6006
p = 0.1502
p = 0.0003
p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0001
p = 0.0007
p0.0103
p = 0.6546
p = 0.0113
p = 0.0280
p = 0.0198
p = 0.9601
p = 0.0793
p = 0.4390
p = 0.4883
p = 0.0049
p < 0.0001
p < 0.0001
p < 0.0001
p = 0.0147
p = 0.0012
p = 0.0001
p = 0.9989
p < 0.0001
p < 0.0001
p = 0.0244
p = 0.3739
p = 0.1318
p = 0.7642
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transduction followed by Lambda Red recombineering mediated removal of the
tetA-sacB cassette by counterselection as described53, leading to quadruple deletion
mutant HA623. HA630 was generated by Lambda Red recombination of a tetRA
resistance cassette into the asd deletion site of HA623. The mutagenesis primers
used are listed in Table 2. Auxotrophic SPI1 effector gene sopE sopE2 sipA triple
mutant H727 was constructed in parent strain SL1344 as described previously31.
The reported avirulence phenotype of the sopE sopE2 sipA mutation was confirmed
by gentamicin protection assay (see Fig. S7D) and by P22 transduction of the wild-
type alleles of asd and alrN to recover prototrophy in resultant strain HA733,
which was then confirmed to be of strongly reduced intestinal virulence in germ-
free mice (histopathological score at day 2 of infection= 2.5 ± 0.5 [mean ± range;
n= 2]; wild-type control= 11).
Luria-Bertani (LB) medium (Sigma-Aldrich) was used as standard bacterial
culture medium. Ampicillin (Sigma; 100 μg/mL), tetracycline (Sigma; 12.5 μg/mL),
kanamycin (Sigma; 50 μg/mL), chloramphenicol (Sigma; 6 μg/mL), nalidixic-acid
(Sigma; 50 μg/mL), meso-diaminopimelic acid (m-Dap; Sigma, 50 μg/mL), and/or
D-alanine (D-Ala; Sigma, 200 μg/mL) were added to the medium as appropriate.
Cellular invasion assays. HeLa (Kyoto) cells were seeded into 24-well dishes and
were grown for 1 day until 80% confluence was obtained. HeLa cells were cultured
Fig. 7 Efficient colonization and immune induction by auxotrophic STm in microbiota-associated mice. a sDMDMm mice were gavaged with a single
dose of 107 CFU of either STmAux (blue open circles, n= 21), STmT3SS− (green squares, n= 9), STmΔssaV (black triangles, n= 5), or wild-type STm (red
triangles, n= 6). Time course of viable bacteria of each strain recoverable from feces. b Lipocalin-2 concentration in cecal contents at day 2, 4, and 28 after
inoculation with the indicated STm strains. Pictures show representative H&E stainings of ceca at day 4 post inoculation with either STmWT or STmAux.
c Representative cecal histology on day 4 after colonization with STmAux, H&E staining, scale bar 100 µm. d Bacterial burden of indicated STm strains
recoverable from mLN, spleen, and liver at day 2, 4, and 28 after initial colonization. e Confocal immunofluorescence microscopy of cecum tissue showing
an epithelial cell invaded by STmAux. Green, STmAux harboring ssag::eGFP reporter plasmid pM973; blue, DNA (DAPI); gray, F-actin (phalloidin). Dotted
yellow lines outline the border of the epithelium facing the intestinal lumen (Lu) and lamina propria (Lp), respectively. Scale bar= 10 µm (n= 6 animals).
f Bacterial burden of indicated STm strains recoverable from mLN, liver, and spleen at day 3 post inoculation in MYD88/TRIF double KO mice (n= 3
animals per treatment group). g Wild-type STm-specific titer of intestinal IgA at day 24 post inoculation of sDMDMm mice with either STmAux (blue open
circles, n= 3 animals) or STmAux T3SS− (green open squares, n= 5 animals). h sDMDMmmice were inoculated by gavage with a single dose of 107 CFU of
either STmAux (blue open circles, n= 5 animals), STmAux T3SS− (green open squares, n= 3 animals), STmAux ΔssaV (black open triangles, n= 4 animals),
or left untreated (n= 5 animals), and at day 28 challenged with 107 CFU wild-type STm (red open triangles). Mice were studied 4 days after challenge (day
32). i Lipocalin-2 concentration in cecal contents quantified at day 32 (4 days after challenge). j Bacterial burden of wild-type STm recoverable from mLN,
liver, and spleen at day 32. Each symbol represents on individual. Statistics: connecting lines connect means (a, f), bars indicate mean (b–e, g, h).
Horizontal dotted lines indicate the lower detection limit (a–h). Panels b–d, g, h were analyzed with a one-way ANOVA and Dunnett’s post hoc test or
unpaired two-tailed t-test (b, c, e). Data shown in a–d are pooled from four independent internally controlled experiments. Data shown in h–j were obtained
from the same experiment. Source data are provided as a Source Data file. Detailed statistical metrics are reported in the Supplementary Statistical
Analysis file.
Table 1 Bacterial strains and plasmids.
Strain (acronym)/plasmid Genetic background Relevant genotype Known
resistances
Comments Origin or
reference
χ4138 (STm) UK-1 Wild-type strain Nal Virulent wild-type control 28
χ9650 (STmΔSPI1 ΔSPI2) UK-1 Δ(avrA-invH::cat) Δ(ssaG-ssaU::
aphT
Nal, Cam, Kan 28
χ9052 UK-1 Δalr3 ΔdadB4 ΔasdA33 68
M736 ATCC 14028s derivate
IR715 (ref. 69)
ΔinvC::aphT Nal, Kan 31
M738 ATCC 14028s derivate
IR715 (ref. 69)
ΔssaV::cat Nal, Cam 31
HA135 (STmAux) UK-1, χ9052 ΔmetC::tetRA Δalr3 ΔdadB4
ΔasdA33
Tet This study
HA618 (STmAux ΔinvC) UK-1, STmAux ΔmetC::tetRA Δalr3 ΔdadB4
ΔasdA33 ΔinvC::aphT
Tet, Kan This study
HA218 (STmAux ΔinvC ΔssaV) UK-1, STmAux ΔmetC::tetRA Δalr3 ΔdadB4
ΔasdA33 ΔinvC::aphT ΔssaV::cat
Tet, Kan, Cam This study
HA208 (STmAux ΔSPI1 ΔSPI2) UK-1 ΔmetC::tetRA Δalr3 ΔdadB4
ΔasdA33 Δ(avrA-invH::cat) Δ(ssaG-
ssaU::aphT
Tet, Kan, Cam This study
pM973 pWKS30 (ref. 70) Amp eGFP under control of the
ssaG promoter
17
SB300 (STm) SL1344 Wild-type strain Str
HA623 SL1344 ΔmetC ΔalrN ΔalrP Δasd Str This study
HA630 (STmAux) SL1344, HA300 ΔmetC ΔalrN ΔalrP Δasd::tetRA Str, Tet Used in Fig. 7 and
corresponding
Supplementary figures
This study
HA705 (STmT3SS−) SL1344, SB300 ΔinvC::aphT ΔssaV::cat Str, Kan, Cam Used in Fig. 7 This study
HA706 (STmΔssaV) SL1344, SB300 ΔssaV::cat Str, Cam Used in Fig. 7 This study
HA702 (STmAux T3SS−) SL1344, SB300 ΔmetC ΔalrN ΔalrP Δasd::tetRA
ΔinvC::aphT ΔssaV::cat
Str, Tet,
Kan, Cam
Used in Fig. 7 This study
HA700 (STmAux ΔinvC) SL1344, SB300 ΔmetC ΔalrN ΔalrP Δasd::tetRA
ΔinvC::aphT ΔinvC::aphT
Str, Tet, Kan Used in Fig. 7 This study
HA727 (STmAux ΔTriple-Eff) SL1344, SB300 ΔmetC ΔalrN ΔalrP Δasd ΔinvC::
aphT ΔinvC::aphT ΔsopE::pGP704
ΔsipA::aphT ΔsopE2::pM218
Str, Tet,
Kan, Cam,
Used in Fig. S7 This study
HA733 (STmΔTriple-Eff) SL1344, SB300 ΔmetC ΔalrP ΔsopE::pGP70 ΔsipA::
aphT ΔsopE2::pM218
Str, Tet,
Kan, Cam
Prototrophic derivative
of HA727
This study
SKI12 (rough STm) SL1344, SB300 ΔwbaP Nal 71
M1525 (SEn) S. Enteritidis 125109 Wild-type strain 72
HA627 (rough SEn) S. Enteritidis 125109 ΔrfbS This study
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in Dulbecco modified Eagle's medium (DMEM) containing 10% fetal bovine serum
(FBS) and incubated at 37 °C under an atmosphere containing 5% CO2. Shortly
before STm infection, the adherent cells were incubated in Hanks’ buffered salt
(HBSS) medium. STm strains were inoculated from a single colony in 10 mL D-Ala
(200 μg/mL) and m-Dap (50 μg/mL) supplemented (optional) 0.3 M sodium-
chloride/LB and incubated at 150 r.p.m., at 37 °C for 16 h. STm cultures were
diluted 1:20 into 40 mL fresh medium and incubated at the same conditions for 5 h.
Subsequently, STm were washed in PBS and HeLa cells were infected with
approximately 3 × 106 CFU STm per well. Fifty minutes after infection, extra-
cellular STm were inactivated by replacing HBSS with DMEM containing 10% FBS
and gentamicin (400 μg/mL) up to a total infection time of 2 h. For the quantifi-
cation of intracellular (=gentamicin protected) STm, HeLa cells were washed in
PBS and subsequently lysed in 0.1% sodium-deoxycholate/PBS. The released
intracellular bacteria were quantified on D-Ala and m-Dap supplemented LB agar
plates.
For differential fluorescent staining of extra- and intracellular STm, HeLa cells
were cultured on glass coverslips and infected as described above. After a total
infection time of 2 h, cells were fixed in 4% PBS-buffered paraformaldehyde. After
incubation in blocking buffer (2% BSA/PBS), the cells were incubated in rabbit-
anti-STm O-antigen group B antiserum (Becton Dickinson) diluted in blocking
buffer, washed twice in blocking buffer, and incubated in goat anti-rabbit CY3
(Jackson Immunoresearch) diluted in blocking buffer. Subsequently, cells were
permeabilized with 0.5% Triton X-100 in PBS, incubated again in blocking buffer,
and stained again with rabbit-anti-STm O-antigen group B antiserum (Becton
Dickinson), washed in blocking buffer, and incubated in a solution of goat anti-
rabbit Alexa Fluor-647 (Jackson Immunoresearch) antibody and DAPI (Sigma).
The coverslips were mounted under Vectashield mounting medium (Vectorlabs)
and examined under a Zeiss Axio Imager M1 fluorescence microscope with a ×63
oil objective and recorded with an AxioCamHR3 camera.
Animal experiments. Animal experiments were performed in accordance to
animal experiment licenses (BE94/11, BE91/14, BE36/15, BE85/17) approved by
the Bernese Cantonal Ethical committee for animal experiments and carried out in
accordance with Swiss Federal law for animal experimentation.
Mice were maintained under axenic barrier conditions at the Clean Mouse
Facility of the University of Bern. The housing conditions in the whole facility are
strictly controlled. The ambient temperature is 23–25 °C and the relative humidity
is 52–60%. All mice received at all times standard diet (Kliba 3307) and water ad
libitum. The genetic background of all mice used was C57BL/6. MYD88−/−
TRIFlps/lps mice54,55 were provided by Bruce A. Beutler, The Scripps Research
Institute, CA, USA and maintained germ free in the Clean Mouse Facility,
University of Bern. NRLC4−/− (also known as Ipaf−/−) mice56 were provided by
V. Dixit, Genentech, and derived germ free in the Clean Mouse Facility, University
of Bern. NOD1−/− NOD2−/− mice57 were provided by Dana Philpott, University
of Toronto ON, Canada, and derived germ free and provided by Elena F. Verdue,
Axenic Gnotobiotic Facility, McMaster University, Hamilton ON, Canada.
Caspase-1/11−/− mice (B6N.129S2-Casp1tm1Flv Casp4del/J58) were purchased from
Table 2 Primers used for bacterial mutagenesis.
Primer name 5′→ 3′ sequence Additional information Applicable
background
STM-metC-tetRA-F TTTGGCAAAATTTTCATCTGTATCACACGTCGCCAGGGTGCA
GATGGTTATATTCATGCTAGTTTAGACATCCAGACGGTTA
AAATCAGGAAACGCAACTTAAGACCCACTTTCACATT
Allelic exchange of metC with TetRA UK-1
STM-metC-tatRA-R GTACTCCTGAATCGTCCGGGATGCCTTGATCCCGGACGCA
ACAAACGCAGACTTTTCCACGGAAATTGTCTGCATATATGTC
CATCCCCGGCAACTTTACTAAGCACTTGTCTCCTG
Allelic exchange of metC with TetRA UK-1
STM-metC-cntr-F ACGCCAGAATCAAACCAATC metC control primer UK-1
STM-metC-cntr-R ATCGCCAGGTAAGAATGACG metC control primer UK-1
STM-asd-TetA-SacB-F GAACCACACGCAGGCCCGATAAGCGCTGCAATAGCC
ACTAATCAAAGGGAAAACTGTCCATATGC
Allelic exchange of asd with TetA-SacB SL1344
STM-asd-TetA-SacB-R CGCGCATACACAGCACATCTCTTTGCAGGAAAAA
AACGCTTCCTAATTTTTGTTGACACTCTATC
Allelic exchange of asd with TetA-SacB SL1344
STM-asd-rmvl-F GAACCACACGCAGGCCCGATAAGCGCTGCAATAGCCACTAA
GCGTTTTTTTCCTGCAAAGAGATGTGCTGTGTATGCGCG
Removal of TetA-SacB cassette SL1344
STM-asd-rmvl-R CGCGCATACACAGCACATCTCTTTGCAGGAAAAAAACGCT
TAGTGGCTATTGCAGCGCTTATCGGGCCTGCGTGTGGTTC
Removal of TetA-SacB cassette SL1344
STM-asd-ctrl-Rv TAAGCGCTGCAATAGCCACT asd control primer SL1344
STM-asd-ctrl-Fw TTGCGACTTTGGCTGCTTTT asd control primer SL1344
STM-alrN-TetA-SacB-F CCCAAGTGGACCGGTCGACGCCTTAGCCTGAATTA
GGTTAATCAAAGGGAAAACTGTCCATATGC
Allelic exchange of alrN with TetA-SacB SL1344
STM-alrN-TetA-SacB-R CAACGTTTGCATAGCGCGCATAACTGATAAAG
GAAGTGAATCCTAATTTTTGTTGACACTCTATC
Allelic exchange of alrN with TetA-SacB SL1344
STM-alrN-rmvl-F CCCAAGTGGACCGGTCGACGCCTTAGCCTGAATTAGGTTAT
TCACTTCCTTTATCAGTTATGCGCGCTATGCAAACGTTG
Removal of TetA-SacB cassette SL1344
STM-alrN-rmvl-R CAACGTTTGCATAGCGCGCATAACTGATAAAGGAAGTGAA
TAACCTAATTCAGGCTAAGGCGTCGACCGGTCCACTTGGG
Removal of TetA-SacB cassette SL1344
STM-alrN-ctrl-Fw GTTTGGCGGCATGATTTGGA alrN control primer SL1344
STM-alrN-ctrl-Rv CACCTTAGGCTGGACGATGG alrN control primer SL1344
STM-alrP-TetA-SacB-F GATGAGTAACTCTCCGTCATTCTTTTAACAAGGAATTCA
ATCCTAATTTTTGTTGACACTCTATC
Allelic exchange of alrP with TetA-SacB SL1344
STM-alrP-TetA-SacB-R CCGGATAAGCGCAAGCGCCACCCGGCCCGCCGCGTAT
TTAATCAAAGGGAAAACTGTCCATATGC
Allelic exchange of alrP with TetA-SacB SL1344
STM-alrP-rmvl-F GATGAGTAACTCTCCGTCATTCTTTTAACAAGGAATTCAATAA
ATACGCGGCGGGCCGGGTGGCGCTTGCGCTTATCCGG
Removal of TetA-SacB cassette SL1344
STM-alrP-rmvl-R CCGGATAAGCGCAAGCGCCACCCGGCCCGCCGCGTATTTATT
GAATTCCTTGTTAAAAGAATGACGGAGAGTTACTCATC
Removal of TetA-SacB cassette SL1344
STM-alrP-ctrl-Fw GGTACGGTTCGTCTGACGTT alrP control primer SL1344
STM-alrP-ctrl-Rv TATTACCGGATGACGGCGTG alrP control primer SL1344
STM-metC-TetA-SacB-F TAGTTTAGACATCCAGACGGTTAAAATCAGGAAA
CGCAACTCCTAATTTTTGTTGACACTCTATC
Allelic exchange of metC with TetA-SacB SL1344
STM-metC-TetA-SacB-R CGGAAATTGTCTGCATATATGTCCATCCCCGGCAA
CTTTAATCAAAGGGAAAACTGTCCATATGC
Allelic exchange of metC with TetA-SacB SL1344
STM-metC-rmvl-F TAGTTTAGACATCCAGACGGTTAAAATCAGGAAACGCAA
CTAAAGTTGCCGGGGATGGACATATATGCAGACAATTTCCG
Removal of TetA-SacB cassette SL1344
STM-metC-rmvl-R CGGAAATTGTCTGCATATATGTCCATCCCCGGCAACTTTA
GTTGCGTTTCCTGATTTTAACCGTCTGGATGTCTAAACTA
Removal of TetA-SacB cassette SL1344
STM-metC-ctrl-Fw GCCAGGGTGCAGATGGTTAT metC control primer SL1344
STM-metC-ctrl-Rv GACGCAACAAACGCAGACTT metC control primer SL1344
STM-asd-TetRA-Fw GCGCGCATACACAGCACATCTCTTTGCAG
GAAAAAAACGCTTTAAGACCCACTTTCACATT
Allelic exchange of asd with TetRA SL1344
STM-asd-TetRA-Rv AACCACACGCAGGCCCGATAAGCGCTGCA
ATAGCCACTACTAAGCACTTGTCTCCTG
Allelic exchange of asd with TetRA SL1344
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The Jackson Laboratory in the form of cryopreserved embryos and transferred into
germ-free recipients in the Clean Mouse Facility, University of Bern. Germ-free
and sDMDMm wild-type C57BL/6 animals, germ-free JH−/− mice59 and RAG−/−
mice60 were maintained at the Clean Mouse Facility, University of Bern.
Gnotobiotic sDMDMm mice have been generated at the Clean Mouse Facility
of the University of Bern by inoculation of germ-free C54BL/6 mice with purified
culture of the murine intestinal bacterial consortium Oligo-MM12 (ref. 38) and
stably maintained in flexible film isolators under strictly axenic conditions.
sDMDMm RAG−/− mice and MYD88−/− TRIFlps/lps mice were generated by co-
housing of the genetically modified germ-free mice with gnotobiotic wild-type
sDMDMm mice for 4 weeks.
SPF C57BL/6 mice were purchased from Charles River (France) and maintained
at the Central Animal Facility of the Department of Biomedical Research,
University of Bern. For infections in the streptomycin pretreatment model24 SPF
mice were pre-treated with 20 mg of streptomycin dissolved in sterile water prior to
infection with STm by gavage.
Infection and colonization experiments were performed under strict aseptic
conditions. Mice were derived and maintained germ free in flexible film isolators61
(including the duration of transient auxotrophic bacterial conditioning) or
autoclaved Sealsafe-plus IVC cages (Tecniplast, Italy; during STm challenge and
short-term infections) at the Clean Mouse Facility (CMF) of the University of Bern.
Animals were provided with autoclaved mouse chow (Kliba 3307) and water ad
libitum. Germ-free status of all animals was routinely monitored using culture-
based and culture-independent methods established by the Clean Mouse Facility,
DKF University of Bern. Mice were infected with 200 μL STm suspension.
Bacteria for enteral inoculation were grown under SPI1-inducing conditions.
Auxotrophic STm were inoculated into 10 mL D-Ala- (200 μg/mL) and m-Dap-
(50 μg/mL) supplemented LB containing 0.3 M NaCl and incubated shaking at
150 r.p.m., at 37 °C for 16 h. The resulting bacterial cultures were diluted 108-fold
in 500 mL fresh medium and incubated under the same conditions for 15 more
hours. STm were harvested by centrifugation (15 min, 4816 × g, 4 °C), washed twice
with cold PBS, and resuspended to the appropriate densities. For peracetic acid
(PAA) inactivation, an aliquot of auxotrophic STm was resuspended in 10 mL 1%
peracetic acid for 1 h at room temperature. The inactivated STm suspension was
washed with PBS and resuspended to the the appropriate density. Sterility of PAA-
killed inocula was confirmed by standard culture methods. Wild-type STm cultures
were inoculated from a single colony in 10 mL 0.3 M sodium-chloride/LB and
incubated at 150 r.p.m., at 37 °C for 16 h. Wild-type STm cultures were diluted 1:20
into 40 mL fresh medium and incubated at the same conditions for 5 h.
Bacterial loads in organs and feces. Organs, feces, and cecum content were
aseptically collected. Organs were homogenized in 0.5 mL 0.5% tergitol/PBS, feces
and cecum content in 0.5 mL PBS using a tissue lyzer (TissueLyzer LT, Qiagen,
50 Hz, 3–5 min, with a stain-less steel bead). Bacterial loads were quantified by
plating on LB agar. Where necessary, D-Ala (200 μg/mL) and m-Dap (50 μg/mL)
were added.
Isolation of intestinal secretory IgA. Intestinal IgA lavages were collected by
rinsing the small intestine with 5 mL of 1% soybean-trypsin inhibitor/0.05 M
EDTA/PBS. The intestinal lavages were spun at 4816 × g, >20 min, 4 °C. The
supernatant was sterile-filtered (0.22 µm cut-off size) to remove bacteria-sized
particles and stored long-term in aliquots frozen at −20 °C.
Immunoglobulin repertoire sequencing. Germ-free C57BL/6 mice were orally
administrated with 3 × 1010 STmAux or STmAux ΔinvC ΔssaV three times at 7-day
intervals. Naïve germ-free mice served as naïve controls. Twenty-eight days post
last administration, ileum and MLN were dissected and snap-frozen in Trizol
reagent (Life Technologies) using liquid nitrogen. Thawed tissues were homo-
genized (Retsch bead-beater) in 1 mL of Trizol reagent. Two hundred microliters
chloroform was added to samples and centrifugation (12,000 × g, 15 min, 4°C) was
performed. The upper phase containing RNA was collected, and RNA was pre-
cipitated with ice-cold isopropanol. After washing once with 75% (v/v) ethanol,
RNA pellet was dried and resuspended in RNase-free water. Nanodrop2000
(Thermo Scientific) was used to quantify RNA concentrations and purity.
To prepare IgA amplicons, cDNA was synthesized by mixing 700 ng of RNA,
1 μL of 2 μM gene specific primer mix (as previously described62, 1 μL of 10 mM
dNTP (containing dATP, dCTP, dGTP, and dTTP at a final concentration of 10
mM, Invitrogen) and topped with dH2O to 13 μL. Samples were heated to 65 °C for
5 min, and then cooled for 1 min on ice. Four microliters 5X first strand buffer
(Invitrogen), 1 μL 782 0.1 M DTT (Invitrogen), 1 μL RNaseOUT (Invitrogen), and
1 μL Superscript III RT enzyme (Invitrogen) were added to each reaction, mixed,
and incubated at 55 °C for 50 min. A heat inactivation at 70 °C for 15 min was done
to stop the reaction. Five microliters of synthesized cDNA library was used as a
template DNA for amplicon PCR PlatinumTaq PCR buffer (Qiagen) following the
manufacturer’s instruction. Primers used in the PCR reaction listed below were
described previously63. PCR products were electrophorized on 1.5% agarose gel
and purified with the QIAquick Gel Extraction kit (Qiagen). The purified DNA was
quantified using Qbit (Thermofisher). Sequencing adapters (Nextera® XT Index
Kit, Illumina) were linked to each amplicon by doing a second PCR. After testing
with a Fragment Analyzer™ (Advanced Analytical), amplicons with sequencing
adaptors were pooled for sequencing on the MiSeq Illumina sequencer using paired
250 bp mode.
For primer sequences used view Table 3.
Antibody repertoire sequencing analysis. B cell IgA receptor heavy chain
libraries were prepared as previously described64 and sequenced on the Illumina
MiSeq platform (2 × 250 cycles, paired-end). Output files were preprocessed (VDJ
alignment, clonotyping) using MiXCR (v3.0.12). Clonotypes were defined by 100%
amino acid sequence identity of CDR3 regions. Annotation of the different seg-
ments was defined by MiXCR according to the nomenclature of the Immunoge-
netics database (IMGT)65. MIXCR output files were further processed in the post-
processing tool-suite: VDJtools66. Further filtering was applied in order to keep
only productive sequences if: (i) they were composed of at least four amino acids
and (ii) had a minimal read count of 2 (ref. 63) and were in-frame.
Table 3 Primers used for antibody repertoire sequencing.
IgH Forward Mix 5′→ 3′ sequence Illumina Adapter sequence read 1+Diversity region+VH 5′-specific region
IgH-UAd-fw1 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAKGTRMAGCTTCAGGAGTC
IgH-UAd-fw2 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTBCAGCTBCAGCAGTC
IgH-UAd-fw3 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNCAGGTGCAGCTGAAGSASTC
IgH-UAd-fw4 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTCCARCTGCAACARTC
IgH-UAd-fw5 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNCAGGTYCAGCTBCAGCARTC
IgH-UAd-fw6 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNCAGGTYCARCTGCAGCAGTC
IgH-UAd-fw7 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNCAGGTCCACGTGAAGCAGTC
IgH-UAd-fw8 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTGAASSTGGTGGAATC
IgH-UAd-fw9 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAVGTGAWGYTGGTGGAGTC
IgH-UAd-fw10 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTGCAGSKGGTGGAGTC
IgH-UAd-fw11 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAKGTGCAMCTGGTGGAGTC
IgH-UAd-fw12 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTGAAGCTGATGGARTC
IgH-UAd-fw13 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTGCARCTTGTTGAGTC
IgH-UAd-fw14 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGARGTRAAGCTTCTCGAGTC
IgH-UAd-fw15 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAAGTGAARSTTGAGGAGTC
IgH-UAd-fw16 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNCAGGTTACTCTRAAAGWGTSTG
IgH-UAd-fw17 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNCAGGTCCAACTVCAGCARCC
IgH-UAd-fw18 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGATGTGAACTTGGAAGTGTC
IgH-UAd-fw19 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGNNNNGAGGTGAAGGTCATCGAGTC
IgH Reverse Primer 5′→ 3′ sequence Illumina Adapter sequence read 2+Diversity region+ IgA constant region specific
IgA-const-rev GTCTCGTGGGCTCGGAGATGTGTATAAGAGACANNNNGAGCTCGTGGGAGTGTCAGTG
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Repertoire overlap was measured by calculating the geometric mean of relative
overlap frequencies between CDR3 amino acid sequence usage. The relative
overlap similarity was represented on a multi-dimensional scaling (MDS) plot.
Histology and pathological evaluation of cecum tissue. For each individual,
proximal and distal cecum tissue was embedded in OCT compound (Tissue Tek,
DC6994583) and frozen in liquid nitrogen. Three consecutive 6 μm cryosections of
each tissue were mounted on glass slides and stained with hematoxylin and eosin
following standard protocols. Histopathology was scored in a blinded manner
according to the severity of submucosal edema (0–3 score points), the number of
polymorphonuclear granulocytes per high-power field in the lamina propria
(0–4 score points), reduced numbers of goblet cells (0–3 score points), and epi-
thelial damage (0–3 score points) resulting in a total score of 0–13 points24. The
mean combined pathological score of proximal and distal cecum is reported.
Fluorescence microscopy of tissue invaded STm. Tissue invaded intracellular
STm harboring ssaG::eGFP reporter plasmid pM973 were visualized and quantified
in cecum cryosections prepared from paraformaldehyde-fixed and cryo-embedded
cecum tissue as described previously17. Sections were stained with DAPI (Sigma,
diluted 1:2000) and Phalloidin ATTO 647 (Sigma, diluted 1:500). Up to 12 non-
consecutive sections per animal were quantified visually using a Zeiss AXIO
Imager.M1 microscope equipped with an EC-Plan-NEOFLUAR 40C/1.3 Oil
objective and ×10/23 oculars. One high-power field measures approx. 40,000 µm2.
Quantitation was carried out in a blinded manner. Images were recorded on a Zeiss
LSM710 laser scanning confocal microscope using the Zeiss ZEN 3.1 software.
Images were analyzed with the Image J Fiji package.
mRNA quantification in cecal tissue by qPCR. Cecum tissue was collected
6 h after infection. Immediately, the tissue was washed in PBS and preserved in
RNAlater (Qiagen). The total RNA was extracted from approximately 15 mg tissue,
using the RNeasy mini kit (Qiagen). The extraction quality was assessed with
Agilent RNA 600 Nano Kit (Qiagen) and reached minimally RIN 9. In total,
5 μg mRNA samples were reversed with RT2 easy first strand kit (Qiagen). cDNA
libraries were analyzed in a Viia7 Real-Time PCR System and the Viia7 Real-Time
PCR System acquisition software (Thermo Scientific) using a the RT2 profiler PCR
array quantifying murine Crohn’s disease-related markers (PAMM-169Z, Qiagen)
and SYBR green reagents (Qiagen). Five housekeeping genes (Actb, B2m,
Gapdh, Gusb, and Hsp90ab1) were averaged and used for calculating ΔCT
(=CTsample−CThouskeeping). The upper CT limit was fixed to 35 cycles.
Enzyme-linked immunosorbent assays (ELISA). Total lipocalin-2 concentrations
of cecum content and fecal pellets were determined by sandwich ELISA using a
commercial mouse lipocalin- 2/NGAL ELISA DuoSet (R&D, DY1857), according
to the manufacturer’s instructions. Immunoglobulin A (IgA) concentrations were
quantified from mouse intestinal lavages by sandwich ELISA. ELISA plates were
coated with goat anti-mouse IgA (Southern Biotech, 1040-01) and IgA was
detected with a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgA
(A4789, Sigma). A purified monoclonal IgA isotype antibody (Becton Dickinson,
clone M18-254, 553476) served as standard. Absorbance was measured in a 96-
microplate reader (VarioskanFlash, version 4.00.53) at 405 nm. Lipocalin-2 and
IgA titers were analyzed in Prism 8 for Windows (GraphPad software Inc). −EC50
of each sample/standard was calculated by a four-parameter curve fitting.
Live bacterial flow cytometry. Live bacterial flow cytometry quantification of
bacterial-specific intestinal IgA titers (expressed as LogEC50 values) were deter-
mined as previously described in ref. 25. Briefly, STm were cultured under SPI1-
inducing conditions67 as described in the Cellular Invasion Assays section. Sub-
sequently, 1 mL of the culture was pelleted at 4816 × g in a Heraeus Fresco 21
centrifuge. The pellet was washed and resuspended to a density of 107 CFU/mL in
sterile-filtered 2% BSA/0.005% NaN3/PBS. Intestinal IgA lavages were collected as
described above. Intestinal lavages were serially diluted in sterile-filtered 2% BSA/
0.005% NaN3/PBS. Serially diluted Ig-solutions and bacterial suspension were
mixed 1:1 and incubated at 4 °C for 1 h. Bacteria were washed twice in sterile-
filtered 2% BSA/0.005% NaN3/PBS before re-suspension in monoclonal FITC-anti-
mouse IgA (clone 10.3; Becton Dickinson) or PE-anti-mouse IgG1 (clone A85-1;
Becton Dickinson) and FITC-anti- mouse IgG2b (clone R12-3; Becton Dickinson).
After a further hour of incubation, the bacteria were washed once with PBS/2%
BSA/0.005% NaN3/PBS and then resuspended in 2% paraformaldehyde (PFA)/PBS
for acquisition on a Becton Dickinson FACSArray SORP or Beckman Coulter
Cytoflex S using FSc (forward scatter) and SSc (side scatter) parameters in loga-
rithmic mode. Flow cytometric gating strategy is shown in Fig. S15. Data were
analyzed using FlowJo software (Tree Star), and titers were calculated by fitting
four-parameter logistic curves25.
Statistics. Statistics were analyzed using Prism 8 for Windows (GraphPad software
Inc.). The specific statistical tests used are indicated in the figure legends. Detailed
statistical information is provided in the statistical data analysis file available online
in the supplementary material.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The dataset supporting the conclusions of this article is available as a Source Data file.
The raw data underlying Supplementary Fig. 9 (IgA repertoire sequencing) are in the
European Nucleotide Archive under ENA accession PRJEB37168 [https://www.ebi.ac.uk/
ena/data/view/PRJEB37168]. Preprocessed clonotype amino acid sequences and
metadata description are available in the Supplementary Data. All relevant data are
available from the authors.
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